S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
NASDAQ:MASI

Masimo Stock Forecast, Price & News

$283.55
-1.22 (-0.43 %)
(As of 09/24/2021 04:00 PM ET)
Add
Compare
Today's Range
$281.72
$288.27
50-Day Range
$261.36
$285.24
52-Week Range
$205.10
$288.27
Volume219,261 shs
Average Volume309,816 shs
Market Capitalization$15.61 billion
P/E Ratio73.46
Dividend YieldN/A
Beta0.79
30 days | 90 days | 365 days | Advanced Chart
Receive MASI News and Ratings via Email

Sign-up to receive the latest news and ratings for Masimo and its competitors with MarketBeat's FREE daily newsletter.


Masimo logo

About Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.89 out of 5 stars

Medical Sector

675th out of 1,351 stocks

Electromedical Equipment Industry

17th out of 31 stocks

Analyst Opinion: 1.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Masimo (NASDAQ:MASI) Frequently Asked Questions

Is Masimo a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Masimo stock.
View analyst ratings for Masimo
or view top-rated stocks.

What stocks does MarketBeat like better than Masimo?

Wall Street analysts have given Masimo a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Masimo wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Masimo's next earnings date?

Masimo is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for Masimo
.

How were Masimo's earnings last quarter?

Masimo Co. (NASDAQ:MASI) issued its quarterly earnings results on Monday, July, 26th. The medical equipment provider reported $0.94 EPS for the quarter, topping the consensus estimate of $0.90 by $0.04. The medical equipment provider earned $300.78 million during the quarter, compared to analyst estimates of $295.60 million. Masimo had a trailing twelve-month return on equity of 15.17% and a net margin of 19.00%. Masimo's quarterly revenue was down .1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.85 EPS.
View Masimo's earnings history
.

How has Masimo's stock been impacted by COVID-19?

Masimo's stock was trading at $182.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MASI stock has increased by 55.3% and is now trading at $283.55.
View which stocks have been most impacted by COVID-19
.

What guidance has Masimo issued on next quarter's earnings?

Masimo issued an update on its FY 2021 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share (EPS) guidance of $3.850-$3.850 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.770. The company issued revenue guidance of $1.22 billion-$1.22 billion, compared to the consensus revenue estimate of $1.21 billion.

What price target have analysts set for MASI?

5 analysts have issued 12 month price objectives for Masimo's stock. Their forecasts range from $276.00 to $310.00. On average, they expect Masimo's share price to reach $292.75 in the next year. This suggests a possible upside of 3.2% from the stock's current price.
View analysts' price targets for Masimo
or view top-rated stocks among Wall Street analysts.

Who are Masimo's key executives?

Masimo's management team includes the following people:
  • Joe E. Kiani, Chairman & Chief Executive Officer
  • Bilal Muhsin, Chief Operating Officer
  • Micah Young, Chief Financial Officer & Executive Vice President
  • Yongsam Lee, Chief Information Officer & Executive VP
  • Anand Sampath, Executive VP-Operations & Clinical Research

What is Joe E. Kiani's approval rating as Masimo's CEO?

136 employees have rated Masimo CEO Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among Masimo's employees.

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), The Trade Desk (TTD), The Walt Disney (DIS) and Twilio (TWLO).

What is Masimo's stock symbol?

Masimo trades on the NASDAQ under the ticker symbol "MASI."

Who are Masimo's major shareholders?

Masimo's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.20%), Vanguard Group Inc. (8.52%), FMR LLC (3.78%), Ownership Capital B.V. (3.52%), State Street Corp (3.09%) and Invesco Ltd. (2.09%). Company insiders that own Masimo stock include Adam Mikkelson, Anand Sampath, Bilal Muhsin, Craig B Reynolds, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee.
View institutional ownership trends for Masimo
.

Which institutional investors are selling Masimo stock?

MASI stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., FMR LLC, Massachusetts Financial Services Co. MA, Neuberger Berman Group LLC, First Trust Advisors LP, State of Michigan Retirement System, Swiss National Bank, and Wells Fargo & Company MN. Company insiders that have sold Masimo company stock in the last year include Anand Sampath, Bilal Muhsin, Craig B Reynolds, Joe E Kiani, Micah W Young, and Thomas Samuel Mcclenahan.
View insider buying and selling activity for Masimo
or view top insider-selling stocks.

Which institutional investors are buying Masimo stock?

MASI stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Macquarie Group Ltd., Korea Investment CORP, RTW Investments LP, Vaughan Nelson Investment Management L.P., Champlain Investment Partners LLC, Ensemble Capital Management LLC, and Citigroup Inc..
View insider buying and selling activity for Masimo
or or view top insider-buying stocks.

How do I buy shares of Masimo?

Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Masimo's stock price today?

One share of MASI stock can currently be purchased for approximately $283.55.

How much money does Masimo make?

Masimo has a market capitalization of $15.61 billion and generates $1.14 billion in revenue each year. The medical equipment provider earns $240.30 million in net income (profit) each year or $3.60 on an earnings per share basis.

How many employees does Masimo have?

Masimo employs 5,300 workers across the globe.

When was Masimo founded?

Masimo was founded in 1989.

What is Masimo's official website?

The official website for Masimo is www.masimo.com.

Where are Masimo's headquarters?

Masimo is headquartered at 52 DISCOVERY, IRVINE CA, 92618.

How can I contact Masimo?

Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at (949) 297-7000 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.